向整合素α2以克服慢性髓性白血病细胞中伊马替尼抗性
Yalda Hekmatshoar1, Tulin Ozkan2, Arzu Zeynep Karabay3
1Department of Medical Biology, School of Medicine, Altinbas University, 34147 Istanbul, Turkey.
Biomolecules
|September 27, 2025
概括
向整合素α2 (ITGA2) 可能克服慢性髓性白血病 (CML) 中的意马替尼抗性. 用E7820抑制ITGA2降低了细胞活力和诱导细胞亡,提供了一个新的CML治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 血液学 血液学 血液学
背景情况:
- 慢性髓性白血病 (CML) 是由BCR-ABL融合基因驱动的.
- 伊马替尼布耐药性是CML治疗的一个重大挑战.
- 综合素α2 (ITGA2) 与癌症进展和耐药性有关.
研究的目的:
- 研究ITGA2在CML中对伊马替尼布耐药性的作用.
- 评估ITGA2抑制剂 (E7820) 在克服伊马替尼布耐药性的有效性.
主要方法:
- 使用了对伊马替尼布敏感 (K562S) 和耐药 (K562R) 的CML细胞系.
- 用ITGA2抑制剂E7820,伊马替尼或组合疗法治疗的细胞.
- 评估了细胞活力,细胞亡,基因表达 (BAX,BIM,BCL2),蛋白质水平和MDR1活性.
主要成果:
- 在对伊马替尼布耐药的K562R细胞中,ITGA2过度表达.
- E7820治疗降低了细胞活力,并在敏感细胞和耐药细胞中诱导了亡.
- 组合疗法增强了耐药细胞中的亲亡基因表达和减少了抗亡基因表达,也降低了MDR1活性.
结论:
- 过度表达ITGA2有助于在CML中产生意马替尼抗性.
- 用E7820针对ITGA2显示出克服意马替尼抗性的潜力.
- 抑制ITGA2为耐伊马替尼布的CML患者提供了一种新的治疗策略.
关键词:
E782020 E782020 E782020 E782020 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E7820 E781 E781 E781 E781 E781 E782 E781 E782 E781 E781 E782 E781 E782 E781 E782 E781 E782 E781 E781 E782 E782 E782 E7 E782 E7 E7 E7 E7 E8 E8 E7 E8 E8 E8 E8 E8 E9 E9 E8 E9 E9 E9 E9 E9 E9 E8 E9 E9 E9 E9 E9 E9 E9 E9 E9 是 是 是 是 是 是 是 是 是 是 是 是 是 是 是 是 是 是 是 是 是 是 是 是 是 是 是 是 是 是 是 是灭症 (apoptosis) 是一种死亡的过程.慢性骨髓性白血病 慢性骨髓性白血病产生对伊马替尼布的耐药性.整合素 α2 的组成部分.相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Intracellular Signaling Affects Focal Adhesions
3.5K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
3.5K
Activation of Integrins
4.9K
Integrins bind ligands and transmit information from outside the cell to inside or vice-versa through an "outside-in signaling" or "inside-out signaling."
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding...
4.9K


